TY - JOUR
T1 - Patient values and preferences regarding VTE disease
T2 - A systematic review to inform American Society of Hematology guidelines
AU - Etxeandia-Ikobaltzeta, Itziar
AU - Zhang, Yuan
AU - Brundisini, Francesca
AU - Florez, Ivan D.
AU - Wiercioch, Wojtek
AU - Nieuwlaat, Robby
AU - Begum, Housne
AU - Cuello, Carlos A.
AU - Roldan, Yetiani
AU - Chen, Ru
AU - Ding, Chengyi
AU - Morgan, Rebecca L.
AU - Riva, John J.
AU - Zhang, Yuqing
AU - Charide, Rana
AU - Agarwal, Arnav
AU - Balduzzi, Sara
AU - Morgano, Gian Paolo
AU - Yepes-Nuñez, Juan Jose
AU - Rehman, Yasir
AU - Neumann, Ignacio
AU - Schwab, Nicole
AU - Baldeh, Tejan
AU - Braun, Cody
AU - Rodriguez, Maria Francisca
AU - Schunemann, Holger J.
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/3/10
Y1 - 2020/3/10
N2 - Values and preferences relate to the importance that patients place on health outcomes (eg, bleeding, having a deep venous thrombosis) and are essential when weighing benefits and harms in guideline recommendations. To inform the American Society of Hematology guidelines for management of venous thromboembolism (VTE) disease, we conducted a systematic review of patients' values and preferences related to VTE. We searched Medline, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature from inception to April of 2018 (PROSPEROCRD42018094003). We included quantitative and qualitative studies.We followed Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance for rating the certainty and presenting findings for quantitative research about the relative importance of health outcomes and a grounded theory approach for qualitative thematic synthesis. We identified 14 quantitative studies (2465 participants) describing the relative importance of VTE-related health states in a widely diverse population of patients, showing overall small to important impact on patients' lives (certainty of the evidence from low to moderate). Additionally, evidence from 34 quantitative studies (6424 participants) and 15 qualitative studies (570 participants) revealed that patients put higher value on VTE risk reduction than on the potential harms of the treatment (certainty of evidence from low to moderate). Studies also suggested a clear preference for oral medication over subcutaneous medication (moderate certainty). The observed variability in health state values may be a result of differences in the approaches used to elicit them and the diversity of included populations rather than true variability in values. This finding highlights the necessity to explore the variability induced by different approaches to ascertain values.
AB - Values and preferences relate to the importance that patients place on health outcomes (eg, bleeding, having a deep venous thrombosis) and are essential when weighing benefits and harms in guideline recommendations. To inform the American Society of Hematology guidelines for management of venous thromboembolism (VTE) disease, we conducted a systematic review of patients' values and preferences related to VTE. We searched Medline, Embase, Cochrane Central Register of Controlled Trials, PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature from inception to April of 2018 (PROSPEROCRD42018094003). We included quantitative and qualitative studies.We followed Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidance for rating the certainty and presenting findings for quantitative research about the relative importance of health outcomes and a grounded theory approach for qualitative thematic synthesis. We identified 14 quantitative studies (2465 participants) describing the relative importance of VTE-related health states in a widely diverse population of patients, showing overall small to important impact on patients' lives (certainty of the evidence from low to moderate). Additionally, evidence from 34 quantitative studies (6424 participants) and 15 qualitative studies (570 participants) revealed that patients put higher value on VTE risk reduction than on the potential harms of the treatment (certainty of evidence from low to moderate). Studies also suggested a clear preference for oral medication over subcutaneous medication (moderate certainty). The observed variability in health state values may be a result of differences in the approaches used to elicit them and the diversity of included populations rather than true variability in values. This finding highlights the necessity to explore the variability induced by different approaches to ascertain values.
UR - https://www.scopus.com/pages/publications/85082320321
U2 - 10.1182/bloodadvances.2019000462
DO - 10.1182/bloodadvances.2019000462
M3 - Article
C2 - 32150612
AN - SCOPUS:85082320321
SN - 2473-9529
VL - 4
SP - 953
EP - 968
JO - Blood Advances
JF - Blood Advances
IS - 5
ER -